University of Pittsburgh engineers have developed a real-time position tracking device designed to stabilize active drift at a nanometer precision. This innovative approach leverages an embedded algorithm based on phase shift from the signal's first harmonic in the Fourier domain, significantly enhancing the speed and precision of position estimation in real-time drift tracking experiments.
Description
The COVID-19 antigen test offers an advancement in diagnostic technology by significantly reducing the time required to obtain results, from hours or days with traditional methods to less than 5 minutes. This rapid testing capability is achieved without the need for complex sample processing or expensive equipment, making it a highly accessible solution in various settings.
Applications
- Point-of-Care Diagnostics
- Public Health Screening
- Home Testing Kits
Advantages
The rapid COVID-19 antigen test offers significant advantages over existing diagnostic methods. It provides fast and accurate results within five minutes, making it ideal for point-of-care and mass screening applications. Unlike NAATs, which require specialized equipment and trained personnel, this test utilizes a simple, low-cost platform that can be operated with minimal training. The sc-SWCNT-based FET technology ensures high sensitivity and specificity, crucial for identifying asymptomatic carriers and controlling outbreaks. Additionally, the test's ability to deliver immediate results reduces the waiting time and potential delays associated with current testing methods, significantly enhancing the efficiency of COVID-19 containment efforts.
Invention Readiness
Researchers utilized sc-SWCNT-based FET technology to create a prototype capable of detecting SARS-CoV-2 antigens in clinical samples such as nasopharyngeal swabs. The high-throughput screening process evaluated over 100,000 compounds to identify the most effective binders for NAMPT. The top 360 compounds underwent further testing in a cell-based NAD+ assay, with the top three hits demonstrating increased NAD+ levels in iPSC-derived neurons. A comprehensive library of 1.6 million compounds was screened to find structurally similar molecules, resulting in the synthesis of over 100 novel compounds. Further testing confirmed that these compounds are metabolically stable and capable of increasing NAD+ levels by 25%, with doses believed to be biologically meaningful at less than 500 nM. One compound showed potential in a NAMPT-independent manner, offering an additional strategy to target aging-related diseases. The rapid COVID-19 antigen test is now in the prototype stage, ready for broader implementation and further clinical validation.
IP Status
https://patents.google.com/patent/US20220365078A1
